uniQure Announces 2016 Financial Results and Provides Update on Company Progress
15 mars 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 15, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with...
uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
03 mars 2017 07h00 HE
|
uniQure N.V.
-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling Manufacturing Excellence -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V....
uniQure Announces Presentations at Upcoming March Conferences
01 mars 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Presentations at Upcoming February Conferences
06 févr. 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following...
uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B
30 janv. 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that AMT-060, its proprietary,...
uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs
25 janv. 2017 07h00 HE
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Alexander Kuta,...
uniQure Outlines Key Initiatives for 2017 and Vision for 2018
09 janv. 2017 07h00 HE
|
uniQure N.V.
-- Preparations Underway for Late-Stage Development in Hemophilia B-- Three Clinical-Stage Programs by 2018 Including One Pivotal and Two Proof-of-Concept Studies-- Company Strengthened Following...
uniQure Appoints Matthew Kapusta as Chief Executive Officer
19 déc. 2016 07h00 HE
|
uniQure N.V.
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its Board of Directors has unanimously approved the appointment of Matthew Kapusta as Chief Executive Officer...
uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
03 déc. 2016 15h51 HE
|
uniQure N.V.
-- Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylactic FIX Replacement Therapy and Only One Spontaneous Bleed Reported -- Low-Dose Cohort Shows Sustained...
uniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School
02 déc. 2016 07h04 HE
|
uniQure N.V.
Amsterdam, The Netherlands, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Lexington, MA and Amsterdam, the Netherlands, December 2, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today...